The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessAbstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,001–3,100 of 3,967
Bleinc, A., Blin, T., Legué, S., Mankikian, J., Plantier, L., & Marchand-Adam, S. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.03.004 · Cited by 1
Oral Health and Wellbeing of Patients with Idiopathic Pulmonary Fibrosis
Barczyk, A., Białas, A. J., Piotrowski, W. J., et al. (2023) · Journal of Health Study and Medicine · doi:10.2478/jhsm-2023-0001 · Cited by 1
A Test to Comprehensively Capture the Known Genetic Component of Familial Pulmonary Fibrosis
Villeneuve, J., Tremblay, É., Gaudreault, N., Armero, V. E. S., Boudreau, D. K., Li, Z., Renaut, S., Dion, G., & Bossé, Y. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0009ma · Cited by 2
Mullor, M. M. G., Arenas-Jiménez, J. J., Vacas, A. U., García‐Manso, I. G., Pérez, J. L. P., Serra, N. S., & Sevila, R. G. (2024) · Radiología (English Edition) · doi:10.1016/j.rxeng.2023.03.006 · Cited by 1
Aburto, M., Rodríguez-Portal, J. A., Fernández‐Fabrellas, E., Sevila, R. G., Lara, S. H., de Miguel, E. B., Ruiz, J. M. G., Molina‐Molina, M., Safont, B., Mayoral, R. G., et al. (2024) · Open Respiratory Archives · doi:10.1016/j.opresp.2024.100334 · Cited by 1
Repositioning compounds for idiopathic pulmonary fibrosis treatment: seeking the future in the past
Crestani, B. (2024) · European Respiratory Journal · doi:10.1183/13993003.00678-2024 · Cited by 1
Gold( i )-catalyzed synthesis of N -alkenyl 2-pyridonyl sec -amines
Karatavuk, A. O. (2024) · Organic & Biomolecular Chemistry · doi:10.1039/d4ob00815d · Cited by 1
Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis
Matson, S. M. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1208ed · Cited by 1
Kang, J., Lee, K. H., Lee, J. H., Jeong, Y. Y., Choi, S. M., Kim, H. C., Park, J. H., Lee, H.-K., Yong, S. J., Choi, H. S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451447 · Cited by 2
Inada, S., Nakashima, T., Masuda, T., Shimoji, K., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03933-8 · Cited by 2
Current approaches for the treatment of chronic respiratory disorders and limitations
Yeung, S., Loo, C., Saeid, A. B., & Lee, W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-27345-2.00002-3 · Cited by 4
Prevalence, Clinical Features, and Outcomes of Young Patients with Idiopathic Pulmonary Fibrosis
Lee, J., Kim, K., Nam, J. H., Choi, J. Y., Rhee, C. K., & Jo, Y. S. (2024) · Respiration · doi:10.1159/000541692 · Cited by 2
Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis
Wang, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00263 · Cited by 1
Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States
Cadham, C. J., Reicher, J. J., Muelly, M. C., & Hutton, D. W. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12506-1 · Cited by 2
Predicting Failure: Can Blood Biomarkers Identify Likely Treatment Non‐Responders in IPF ?
Maher, T. M. (2025) · Respirology · doi:10.1111/resp.70041 · Cited by 1
Ma, H., Huang, Z., Jeet, S., Emerson, C., Bender, H. S., Ren, Q., & Ding, N. (2025) · iScience · doi:10.1016/j.isci.2025.112778 · Cited by 1
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
Prospects of pirfenidone use in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis
Трушенко, Н. В., Levina, I. A., Lavginova, B. B., Suvorova, O., & Avdeev, S. N. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-201 · Cited by 2
Prognosis and prognostic factors for chronic fibrosing idiopathic interstitial pneumonias
Nishikiori, H., & Chiba, H. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.005 · Cited by 1
Hur, J., Rhee, C. K., Choi, J. Y., & Jo, Y. S. (2025) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2025.102376 · Cited by 5
Achaiah, A., Fraser, E., Saunders, P., Hoyles, R. K., Benamore, R. E., & Ho, L. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03825-4 · Cited by 2
Stratifying GAP Stages by MUC5B rs35705950 T-Allele Carriage Refines Survival Prediction in IPF
van der Vis, J. J., Prasse, A., Renzoni, E. A., Stock, C. J. W., Maher, T. M., Bonella, F., Borie, R., Crestani, B., Wuyts, W. A., Molyneaux, P. L., et al. (2025) · Lung · doi:10.1007/s00408-025-00837-z · Cited by 1
Discovery of novel anti-fibrotics through phenotypic screening
Lapthorn, A. R., Harding, S. L., Feltham, K. M., Ilg, M. M., & Cellek, S. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104450 · Cited by 1
Regional Medical Collaboration May Lead to Early Detection of Interstitial Lung Disease
Zaizen, Y., Tominaga, M., Matama, G., Ichikawa, Y., Gohara, R., Hiyama, J., Ide, S., Kamimura, T., Kinoshita, M., Kitasato, Y., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14175923 · Cited by 1
Tagami, Y., Kawai, M., Okamura, K., & Kitamura, H. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0021 · Cited by 1
Genetic Familial Interstitial Lung Disease
Fernandez, R. J., & Kropski, J. A. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.07.008 · Cited by 1
Impact of medications on lung function in fibrotic hypersensitivity pneumonitis
Abe, T., Okamoto, T., Shimamura, T., Ejima, M., Sonoda, S., Shirai, T., Ishizuka, M., Furusawa, H., Tateishi, T., Hanazawa, R., et al. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.09.001 · Cited by 2
Interstitial Lung Disease in 2025—Progress, Challenges, and Hope Ahead
Sehgal, S., & Mehta, A. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186673 · Cited by 1
“Therapeutically, the last transformative breakthrough in ILD came in 2014 with the introduction of antifibrotic agents, which slowed IPF disease progression for the first time and later demonstrated benefits across a broader spectrum of progressive fibrosing ILD [3,4].”
Kass-Gergi, S., Holcomb, N. P., Maiden, M. M., Eisenlohr, L. C., & Vaughan, A. E. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2025 · Cited by 2
Thivent, S., Neder, J. A., Bernard, A., Coudurier, M., Guinot, M., Hérengt, F., Vergès, S., & Marillier, M. (2025) · Experimental Physiology · doi:10.1113/ep091542 · Cited by 1
Wu, Y., & Ou, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00048-2 · Cited by 1
Borghetti, P., D’Angelillo, R. M., Facheris, G., Borghesi, A., Bruni, A., Ceruti, P., Ferrari, K., Filippi, A. R., Ramella, S., Signorelli, D., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108807 · Cited by 2
Renner, A., Vertanen, E., Sutinen, E., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-097246 · Cited by 1
Lee, B., Kwak, H. S., Cho, H. S., et al. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251393075 · Cited by 1
Yüksel, A., Nezalzova, P., & Ulubay, G. (2025) · Archives of Medical Science · doi:10.5114/aoms/210329 · Cited by 1
Kang, M., Deng, Q., Zhang, Y.-Y., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178430 · Cited by 1
Barton, C., Hoffman, M., Cox, N. S., Glenn, L. M., Lee, J. Y. T., Cox, I. A., Goh, N. S. L., Troy, L. K., Mackintosh, J. A., Chambers, D. C., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03442-z · Cited by 1
Self-citationNishikiori, H., Yama, N., Hirota, K., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-04062-5 · Cited by 1
Progressive pulmonary fibrosis
Bajwa, R. U. D., Lancaster, D., Desai, S. R., et al. (2025) · European Radiology · doi:10.1007/s00330-025-12212-w · Cited by 1
Kishaba, T., Higa, M., & Nagano, H. (2025) · Cureus · doi:10.7759/cureus.99813 · Cited by 2
COVID-19 and Interstitial Lung Disease
Carbone, R. G., Nagoti, S., Monselise, A., Wille, K., Puppo, F., & Shah, P. L. (2025) · Medicina · doi:10.3390/medicina62010022 · Cited by 1
Singh, P., Patel, P. K., Kasam, R. K., Lawson, R., Ediga, H. H., Jegga, A. G., & Madala, S. K. (2026) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00204.2025 · Cited by 1
Fares, W. H., & Castagna, M. (2026) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1177/19412711251414386 · Cited by 1
Trboljevac, N., Dimić-Janjić, S., Kontić, M., Omčikus, M., Ilić, B., Marković, F., Postic, A., Isovic, L., Stjepanović, M., & Nenezic, D. (2026) · Medicina · doi:10.3390/medicina62010229 · Cited by 1
“The extent of FVC decline in our cohort matches that observed in the ASCEND and INPULSIS trials, supporting the external validity of our real-world results [15,16].”
Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management
Joshua, J., & Borok, Z. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050224-121458 · Cited by 2
Chen, L., Lan, C., Deng, X., Wu, M., Shao, M., Yang, M., Ma, X., Huang, F., & Wu, H. (2026) · Canadian Respiratory Journal · doi:10.1155/carj/6614209 · Cited by 1
Idiopathic Pulmonary Fibrosis: An Overview
May, J., & Jenkins, G. R. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm50844 · Cited by 3
Lei, S., Li, J., Yang, T., Peng, Z., Xu, Y., Hui, Z., Yan, M., Feng, C., Liu, H., & Tang, W. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178707 · Cited by 2
Okuda, R., Nishioka, Y., Kondoh, Y., Tsubouchi, K., Okamoto, M., Nishiyama, O., Sato, S., Oishi, K., Ishikawa, N., Chiba, H., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag125 · Cited by 1
Song, D., Yang, Y., Li, Z., Song, L., An, B., Yuan, Z., Liu, Y., Su, R., Guo, W., & Xie, L. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100370 · Cited by 1
Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk
Masuda, T., Mochizuka, Y., Suzuki, Y., Kono, M., Matsushima, S., Kato, S., Suzuki, K., Tanaka, K., Koda, K., Masuda, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45792-8 · Cited by 1
Fermoyle, C. C., Mackintosh, J. A., Navaratnam, V. V., Ellis, S. J., Cooper, W. A., Goh, N. S. L., Moodley, Y. P., Reynolds, P. N., Zappala, C. J., Hopkins, P. M.-A., et al. (2026) · Respirology · doi:10.1002/resp.70246 · Cited by 4
Self-citationXu, Q., Li, B., 张超超, Sun, Y., Song, M., Li, Y., Lihua, L. I., Wang, Y., & 于成功 (2026) · Biomaterials Science · doi:10.1039/d5bm00916b · Cited by 2
The immunodynamics of pulmonary fibrosis
Xie, C. H., Ma, Y., Wang, Y., Gul, A., Tang, W., Luo, Q., Xu, W., Wei, Y., Dong, J., & Liu, W. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.04.001 · Cited by 1
Respiratory oscillometry identifies disease progression in interstitial lung disease
Dubé, R., Duran, O. A., Azuelos, I., Cormier, M., Dandurand, R. J., & Assayag, D. (2026) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2025-003900 · Cited by 4
Kasamatsu-Nishimura, T., Kitabatake, M., Ouji-Sageshima, N., Akiyama, Y., Furukawa, R., Saito, S., Hara, A., Kumamoto, M., Hontsu, S., Kawaguchi, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101424 · Cited by 1
Elastokines are potentially associated with a poor prognosis in idiopathic pulmonary fibrosis
Nagel, D. J., Okutani, T., Lopa, S., Mariani, T. J., Sime, P. J., Kottmann, R., & Hocking, D. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-51836-w · Cited by 3
C/EBPγ interacts with C/EBPα and activates the β-catenin pathway in idiopathic pulmonary fibrosis
Pan, X., Xia, C., Gan, Y., Cao, Y., Zhao, M., Liu, H., Zhou, Y., Wang, Y., Li, Z., Li, B., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06245-7 · Cited by 1
Kim, D. Y., Kim, M.-J., Oh, Y. J., Hwang, H. J., Chae, E. J., Lee, S. M., Park, S., Lee, J. C., Seo, J. B., Lee, H. Y., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag245 · Cited by 1
Tirelli, C., Muscato, G., Alaimo, C., Leo, I. D., Mirijaj, S., Pennisi, F., Vancheri, C., & Mondoni, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114172 · Cited by 2
“Pooled analyses of ASCEND and CAPACITY further supported a favorable effect on mortality-related outcomes [60,61].”
InfluentialHonap, S., Dignass, A. U., Jairath, V., et al. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2695461 · Cited by 1
Miao, Y., Hu, Y. Q., Xu, L., Xu, L., Meng, L., Yang, Y., Liu, Z., Yang, Z., Liu, Y.-M., Liu, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118204 · Cited by 1
Diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review
Yoo, J. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0044 · Cited by 1
Definition and diagnostic approach to interstitial lung disease: a narrative review
Kim, K. H. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0049 · Cited by 1
Han, L., Sun, Y., Wang, Y., Wang, Q., Zhang, X., He, H., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1860332 · Cited by 1
Álvarez-Muro, L., Collado-Jiménez, M., Hoyas-Sánchez, C., et al. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.06.016 · Cited by 1
Mycophenolate and azathioprine in fibrotic interstitial lung disease
Pugashetti, J. V., Jee, A. S., Yu, A. R. M., Hammoud, N., Chua, F., Yazbeck, L., Lee, C. T., Liu, G. Y., Adams, T. N., Adegunsoye, A., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag362 · Cited by 3
Li, Y., Song, W., Huan, C., Xu, K., Sun, J., Zhen, X., Ouyang, H., Tang, H., Fan, Q., Zhi, W., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109089 · Cited by 3
Robert, M., Nguyen, Y., Debray, M., Borie, R., Uzunhan, Y., Allenbach, Y., Sacré, K., Terrier, B., Amoura, Z., Comparon, C., et al. (2026) · RMD Open · doi:10.1136/rmdopen-2026-006943 · Cited by 2
Bernardi, E., Mitchell, W., Troyas, C., & Anguita, R. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2724125 · Cited by 1
Forrest, I., & Peel, E. T. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2230-2_9 · Cited by 1
Therapeutische Relevanz des HRCT-Befundes aus pneumologischer Sicht
Suchy, R., & Pfeifer, M. A. (2014) · Der Radiologe · doi:10.1007/s00117-014-2739-y · Cited by 1
A new era of drug therapy for idiopathic pulmonary fibrosis
Crooks, M. G., & Hart, S. P. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70257-7 · Cited by 1
Montero, Á. (2015) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2015.02.006 · Cited by 1
Clinical highlights: messages from Munich
Vogiatzis, I., Marvisi, M., Coolen, J., et al. (2015) · ERJ Open Research · doi:10.1183/23120541.00002-2015 · Cited by 1
Lung transplantation for interstitial lung disease
Paoletti, L., & Whelan, T. P. M. (2014) · Current Respiratory Care Reports · doi:10.1007/s13665-014-0083-3 · Cited by 1
Transcriptional phenotyping of fibrotic lung disease: a new gold standard?
Maher, T. M. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00184-8 · Cited by 1
[Rheumatoid arthritis and combined pulmonary fibrosis and emphysema].
Casares, M. F., Fielli, M., Cristaldo, L., et al. (2015) · PubMed · Cited by 1
Eapen, M. S., Shukla, S., Mahmood, M., McAlinden, K. D., Eri, R. D., Walters, E. H., & Sohal, S. S. (2015) · eCite Digital Repository (University of Tasmania) · Cited by 1
Lara, A., & Schwarz, M. I. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000124 · Cited by 1
Pirfenidone experience in mild-to-moderate idiopathic pulmonary fibrosis in a general hospital
Martínez‐Moreno, J. (2016) · Anales de la Real Academia Nacional de Farmacia · Cited by 1
Mesenchymal Stromal Cell-Based Therapies for Lung Disease
Chambers, D. C. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21082-7_14 · Cited by 1
Idiopathic pulmonary fibrosis can be a transient diagnosis
de Oliveira, M. R., Pereira, D. A. S., Dias, O. M., et al. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016000000003 · Cited by 1
To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress
Jenkins, G. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2311ed · Cited by 1
Deux traitements efficaces pour la fibrose pulmonaire idiopathique : une nouvelle ère commence !
Crestani, B. (2015) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2015.05.011 · Cited by 1
Pirfenidone in idiopathic pulmonary fibrosis: a guide to its use in the EU
Greig, S. L., Lyseng-Williamson, K. A., Kim, E., & Keating, G. M. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0321-6 · Cited by 1
A new era in idiopathic interstitial pneumonias: E pilogue to a review series
Corte, T. J., Collard, H. R., & Wells, A. U. (2016) · Respirology · doi:10.1111/resp.12921 · Cited by 1
The Role of Mesenchymal Stromal Cells in Idiopathic Pulmonary Fibrosis
Río, C. (2016) · International Journal of Stem cell Research & Therapy · doi:10.23937/2469-570x/1410030 · Cited by 1
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
Russell, M., & Sofat, N. (2017) · InTech eBooks · doi:10.5772/66642
Pirfenidone: a breath of fresh air for cGVHD
Ranganathan, P. (2017) · Blood · doi:10.1182/blood-2017-03-772103 · Cited by 1
Pathobiology of Novel Approaches to Treatment
Puglisi, S., & Vancheri, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00002-1 · Cited by 1
Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials
Podolanczuk, A. J., & Lederer, D. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201705-0975ed · Cited by 1
Self-citationReversibility of Renal Fibrosis
Chadjichristos, C. E., Kavvadas, P., Dussaule, J., Abed, A., & Chatziantoniou, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00073-4 · Cited by 1
The Hospitalized Patient with Interstitial Lung Disease: A Hospitalist Primer
Farrand, E. D., Shah, R., & Collard, H. R. (2017) · Journal of Hospital Medicine · doi:10.12788/jhm.2774 · Cited by 1
Szturmowicz, M., Kacprzak, A., & Kuś, J. (2017) · Advances in respiratory medicine · doi:10.5603/arm.2017.0036 · Cited by 3
Chronic Lung Allograft Dysfunction: Phenotypes and the Future
Chambers, D. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_11 · Cited by 1
Cytokine and Anti-Cytokine Agents as Future Therapeutics for Fibrostenosing IBD
Jacob, N., Targan, S. R., & Shih, D. Q. (2018) · Springer eBooks · doi:10.1007/978-3-319-90578-5_5 · Cited by 1
New era of Idiopathic Pulmonary Fibrosis
Kishaba, T. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.08.008 · Cited by 1
Complications of Transbronchial Cryobiopsy
Ravaglia, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_6 · Cited by 1
Idiopathic Pulmonary Fibrosis as a Challenge for the Polish Healthcare System
Kwiecień, M., Budasz-Świderska, M., & Kaczor, M. (2015) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2015.2.1
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.